Latest & greatest articles for thyroid

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on thyroid or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on thyroid and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for thyroid

1. Thyroid cancer: NCCP advice for medical professionals on the management of Thyroid Cancer and Overactive Thyroid Disease in response to the current novel coronavirus (COVID-19) pandemic

Thyroid cancer: NCCP advice for medical professionals on the management of Thyroid Cancer and Overactive Thyroid Disease in response to the current novel coronavirus (COVID-19) pandemic Version: 1 Department: NCCP Radiation Oncology Working Group Update date: 22/04/2020 Code: RO_COVID19_6 Page 1 of 3 NCCP advice for medical professionals on the management of Thyroid Cancer and Overactive Thyroid Disease in response to the current novel coronavirus (COVID-19) pandemic This document relates (...) ://www.gov.ie/en/campaigns/c36c85-covid-19- coronavirus/ ? Ireland’s National Action Plan in response to COVID-19 (Coronavirus) - https://www.gov.ie/en/campaigns/c36c85-covid-19-coronavirus/ 2 Purpose The purpose of this guidance document is to provide guidance to medical professionals on the management of patients with 1) Thyroid cancer (well differentiated, papillary carcinoma) and 2) Patients with overactive thyroid disease. Version: 1 Department: NCCP Radiation Oncology Working Group Update date: 22/04

2020 Health Service Executive (Ireland) - Clinical Guidelines

2. Selpercatinib (Retevmo) - lung and thyroid cancers

Selpercatinib (Retevmo) - lung and thyroid cancers Drug Approval Package: RETEVMO U.S. Department of Health and Human Services Search FDA Submit search Drug Approval Package: RETEVMO Company: Loxo Oncology Inc., a wholly owned subsidiary of Eli Lilly and Company. Application Number: 213246 Approval Date: 05/08/2020 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. FDA Approval Letter and Labeling (PDF) (PDF) FDA Application Review

2020 FDA - Drug Approval Package

3. Thyroid Disease in Pregnancy

Thyroid Disease in Pregnancy Thyroid Disease in Pregnancy | ACOG Clinical Guidance Journals & Publications Patient Education Topics Featured Clinical Topics Hi, Featured Clinical Topics Clinical Guidance Thyroid Disease in Pregnancy Practice Bulletin Number 223 June 2020 Jump to Resources Share By reading this page you agree to ACOG's Terms and Conditions. Nonmembers: Subscribe now to access exclusive ACOG Clinical content, including: ACOG Clinical is designed for easy and convenient access (...) and clinical management issues. Note for Life Fellows: Annual membership dues are waived but there is a discounted annual subscription fee of $95 for access to publications such as the Green Journal, Practice Bulletins, and Committee Opinions. Individual subscriptions include print and online access. . Jump to: Figures & Tables Figure 1. Clinical Algorithm for Management of Thyroid Disease in Pregnancy. Abbreviations: T 3 , triiodothyronine; T 4 , thyroxine; TRAB, thyroid receptor antibodies; TSH, thyroid

2020 American College of Obstetricians and Gynecologists

4. Thyroid hormone treatment: no proof of benefit in asymptomatic subclinical hypothyroidism.

Thyroid hormone treatment: no proof of benefit in asymptomatic subclinical hypothyroidism. Prescrire IN ENGLISH - Spotlight ''Thyroid hormone treatment: no proof of benefit in asymptomatic subclinical hypothyroidism.'', 1 June 2020 {1} {1} {1} | | > > > Thyroid hormone treatment: no proof of benefit in asymptomatic subclinical hypothyroidism. Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |   |  (...)  |   |   |  Spotlight Thyroid hormone treatment: no proof of benefit in asymptomatic subclinical hypothyroidism. According to a systematic review of comparative trials in approximately 2 000 patients, symptomless hypothyroidism discovered incidentally does not require thyroid hormone treatment (levothyroxine). So-called subclinical hypothyroidism is characterised by an elevated blood level of the pituitary hormone TSH but with a normal blood concentration of the thyroid

2020 Prescrire

5. Clinical Practice Guidelines – Thyroid cancer

Clinical Practice Guidelines – Thyroid cancer SPECIAL ARTICLE Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up † S. Filetti 1 , C. Durante 1 , D. Hartl 2,3 , S. Leboulleux 3,4 , L. D. Locati 5 , K. Newbold 6 , M. G. Papotti 7 & A. Berruti 8 , on behalf of the ESMO Guidelines Committee * 1 Department of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy; 2 Department of Head and Neck Oncology, Gustave Roussy, Villejuif; 3 (...) Civili, Brescia, Italy Key words: papillary thyroid cancer, follicular thyroid cancer, anaplastic thyroid cancer, medullary thyroid cancer, management Introduction The aim of clinical practice guidelines is to provide physicians with the best available evidence on particular issues and recom- mendations for the best standards of care. They help health pro- fessionals weigh the bene?ts and the risks of available diagnostic or therapeutic options. Randomised clinical trial (RCT) data on the management

2020 European Society for Medical Oncology

6. A Double-Blind, Randomized Controlled Trial of Pre-incision Wound Infiltration Using Diclofenac Versus Bupivacaine for Post-operative Pain Relief in Open Thyroid and Parathyroid Surgery

A Double-Blind, Randomized Controlled Trial of Pre-incision Wound Infiltration Using Diclofenac Versus Bupivacaine for Post-operative Pain Relief in Open Thyroid and Parathyroid Surgery A Double-Blind, Randomized Controlled Trial of Pre-incision Wound Infiltration Using Diclofenac Versus Bupivacaine for Post-operative Pain Relief in Open Thyroid and Parathyroid Surgery - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features (...) in email: Save Cancel Create a file for external citation management software Create file Cancel Actions Cite Share Permalink Copy Page navigation World J Surg Actions . 2020 Mar 19. doi: 10.1007/s00268-020-05458-6. Online ahead of print. A Double-Blind, Randomized Controlled Trial of Pre-incision Wound Infiltration Using Diclofenac Versus Bupivacaine for Post-operative Pain Relief in Open Thyroid and Parathyroid Surgery , , , Affiliations Expand Affiliations 1 Department of Surgery, University

2020 EvidenceUpdates

7. BTA/SFE statement regarding issues specific to thyroid dysfunction during the COVID -19 pandemic

BTA/SFE statement regarding issues specific to thyroid dysfunction during the COVID -19 pandemic v1 25th March 2020 BTA/SFE statement regarding issues specific to thyroid dysfunction during the COVID -19 pandemic The worldwide spread of the novel coronavirus, COVID-19, has recently been declared a pandemic. This presents many challenges to those of us working in healthcare, and will especially impact individuals with some chronic conditions. Members of the British Thyroid Association (BTA (...) ) and the Society for Endocrinology (SfE) have received numerous queries regarding how this pandemic may affect management of patients with thyroid disease, so we have formulated responses to these questions in order to assist our endocrine and primary care colleagues during this extraordinary time. We acknowledge that the situation is changing rapidly and also that local practice may differ depending on available resources and infrastructure. The British Thyroid Foundation (BTF) and Thyroid Cancer Forum-UK

2020 British Thyroid Association

8. Joint statement from the Society for Endocrinology and the British Thyroid Association regarding ‘Association of Radioactive Iodine Treatment with cancer mortality in patients with hyperthyroidism’

Joint statement from the Society for Endocrinology and the British Thyroid Association regarding ‘Association of Radioactive Iodine Treatment with cancer mortality in patients with hyperthyroidism’ 266 | wileyonlinelibrary.com/journal/cen Clinical Endocrinology. 2020;92:266–267. © 2019 John Wiley & Sons Ltd Received: 1 November 2019 | Revised: 27 November 2019 | Accepted: 29 November 2019 DOI: 10.1111/cen.14136 LE T TER TO THE EDITOR Joint statement from the Society for Endocrinology (...) and the British Thyroid Association regarding ‘Association of Radioactive Iodine Treatment with cancer mortality in patients with hyperthyroidism’ We are aware of the substantial interest shown in the recent publica - tion in JAMA internal medicine by Kitahara et al 1 This retrospective analysis of data from the large multicentre co-operative thyrotoxico- sis therapy follow-up study (CTTFUS) suggests a modest increase in potential risk of death from cancer in people who receive radioiodine therapy

2020 British Thyroid Association

9. Recurrence following hemithyroidectomy in patients with low- and intermediate-risk papillary thyroid carcinoma

Recurrence following hemithyroidectomy in patients with low- and intermediate-risk papillary thyroid carcinoma Recurrence Following Hemithyroidectomy in Patients With Low- And Intermediate-Risk Papillary Thyroid Carcinoma - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Welcome to the new PubMed. For legacy PubMed go to . Clipboard, Search History, and several other advanced features are temporarily unavailable. National (...) Cancel Actions Cite Share Permalink Copy Page navigation Br J Surg Actions . 2020 Feb 5. doi: 10.1002/bjs.11430. Online ahead of print. Recurrence Following Hemithyroidectomy in Patients With Low- And Intermediate-Risk Papillary Thyroid Carcinoma , , Affiliations Expand Affiliation 1 Department of Otolaryngology - Head and Neck Surgery, Kyungpook National University, 130 Dongdeok-ro, Jung-gu, Daegu, 41944, Korea. PMID: 32026467 DOI: Item in Clipboard Recurrence Following Hemithyroidectomy in Patients

2020 EvidenceUpdates

10. Teprotumumab (Tepezza) - Thyroid eye disease

Teprotumumab (Tepezza) - Thyroid eye disease Drug Approval Package: TEPEZZA TEPEZZA " /> U.S. Department of Health and Human Services Search FDA Submit search Drug Approval Package: TEPEZZA Company: Horizon Therapeutics Ireland DAC Application Number: 761143 Approval Date: 01/21/2020 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. FDA Approval Letter and Labeling (PDF) (PDF) FDA Application Review Files (PDF) (PDF) (PDF) (PDF) (PDF

2020 FDA - Drug Approval Package

11. Teprotumumab for the Treatment of Active Thyroid Eye Disease. (Abstract)

Teprotumumab for the Treatment of Active Thyroid Eye Disease. Thyroid eye disease is a debilitating, disfiguring, and potentially blinding periocular condition for which no Food and Drug Administration-approved medical therapy is available. Strong evidence has implicated the insulin-like growth factor I receptor (IGF-IR) in the pathogenesis of this disease.In a randomized, double-masked, placebo-controlled, phase 3 multicenter trial, we assigned patients with active thyroid eye disease in a 1:1 (...) discontinuation.Among patients with active thyroid eye disease, teprotumumab resulted in better outcomes with respect to proptosis, Clinical Activity Score, diplopia, and quality of life than placebo; serious adverse events were uncommon. (Funded by Horizon Therapeutics; OPTIC ClinicalTrials.gov number, NCT03298867, and EudraCT number, 2017-002763-18.).Copyright © 2020 Massachusetts Medical Society.

2020 NEJM

12. Thyroid nodules: diagnostic evaluation based on thyroid cancer risk assessment. Full Text available with Trip Pro

Thyroid nodules: diagnostic evaluation based on thyroid cancer risk assessment. Thyroid nodules are extremely common and can be detected by sensitive imaging in more than 60% of the general population. They are often identified in patients without symptoms who are undergoing evaluation for other medical complaints. Indiscriminate evaluation of thyroid nodules with thyroid biopsy could cause a harmful epidemic of diagnoses of thyroid cancer, but inadequate selection of thyroid nodules for biopsy (...) can lead to missed diagnoses of clinically relevant thyroid cancer. Recent clinical guidelines advocate a more conservative approach in the evaluation of thyroid nodules based on risk assessment for thyroid cancer, as determined by clinical and ultrasound features to guide the need for biopsy. Moreover, newer evidence suggests that for patients with indeterminate thyroid biopsy results, a combined assessment including the initial ultrasound risk stratification or other ancillary testing (molecular

2020 BMJ

13. Thyroid disease: assessment and management

Thyroid disease: assessment and management Thyroid disease: assessment and management NICE guideline Published: 20 November 2019 www.nice.org.uk/guidance/ng145 © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement (...) . Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Thyroid disease: assessment and management (NG145) © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 53Contents Contents Overview 5 Who is it for? 5 Recommendations 6 1.1 Information for people

2019 National Institute for Health and Clinical Excellence - Clinical Guidelines

14. Thyroid hormones treatment for subclinical hypothyroidism Full Text available with Trip Pro

Thyroid hormones treatment for subclinical hypothyroidism Thyroid hormones treatment for subclinical hypothyroidism: a clinical practice guideline | The BMJ Intended for healthcare professionals Username * Password * Edition: Search form Search Search Thyroid hormones... Thyroid hormones treatment for subclinical hypothyroidism: a clinical practice guideline (Published 14 May 2019) Cite this as: BMJ 2019;365:l2006 Visual summary of recommendation or No thyroid hormones Thyroid hormones (...) Levothyroxine Interventions compared Recommendation Population Adults with subclinical hypothyroidism Does not apply to: May not apply to: Including: Women who are or trying to become pregnant Patients with no symptoms (diagnosed after screening) Patients with non-specific symptoms Patients with severe symptoms Patients with TSH above 20 mIU/L Young adults (such as <30 years) Elevated levels of thyroid stimulating hormone (TSH) Normal free T4 (thyroxine) levels We recommend against thyroid hormone therapy

2019 BMJ Rapid Recommendations

15. Lenvatinib (thyroid carcinoma) - Benefit assessment according to §35a Social Code Book V

Lenvatinib (thyroid carcinoma) - Benefit assessment according to §35a Social Code Book V Extract 1 Translation of Sections 2.1 to 2.6 of the dossier assessment Lenvatinib (Schilddrüsenkarzinom) – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 13 May 2019). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. IQWiG Reports – Commission No. A19-19 Lenvatinib (...) (thyroid carcinoma) – Benefit assessment according to §35a Social Code Book V 1 Extract of dossier assessment A19-19 Version 1.0 Lenvatinib (thyroid carcinoma) 13 May 2019 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Lenvatinib (thyroid carcinoma) – Benefit assessment according to §35a Social Code Book V Commissioning agency: Federal Joint Committee Commission awarded on: 15 February 2019

2019 Institute for Quality and Efficiency in Healthcare (IQWiG)

16. Does the ATA Risk Stratification Apply to Patients with Papillary Thyroid Microcarcinoma? (Abstract)

Does the ATA Risk Stratification Apply to Patients with Papillary Thyroid Microcarcinoma? The incidence of papillary thyroid microcarcinoma (PTMC) has increased over the past decade. The American Thyroid Association (ATA) suggests that these patients may undergo either thyroid lobectomy or active surveillance. It remains unclear whether there exists a subgroup of PTMC patients who may benefit from more aggressive treatment due to increased risk of recurrence.We retrospectively reviewed 357

2019 EvidenceUpdates

17. Recommendation on screening adults for asymptomatic thyroid dysfunction in primary care

Recommendation on screening adults for asymptomatic thyroid dysfunction in primary care Recommendation on screening adults for asymptomatic thyroid dysfunction in primary care | CMAJ Main menu User menu Search Search for this keyword Search for this keyword Guideline Recommendation on screening adults for asymptomatic thyroid dysfunction in primary care Richard Birtwhistle , Kate Morissette , James A. Dickinson , Donna L. Reynolds , Marc T. Avey , Francesca Reyes Domingo , Rachel Rodin (...) of Family Medicine and Community Health Sciences (Dickinson), University of Calgary, Alta.; Dalla Lana School of Public Health and Department of Family and Community Medicine (Reynolds), University of Toronto, Ont.; Department of Psychiatry (Thombs), Jewish General Hospital and McGill University, Montréal, Que. KEY POINTS The Canadian Task Force on Preventive Health Care strongly recommends against screening for thyroid dysfunction in asymptomatic nonpregnant adults. Screening for thyroid dysfunction

2019 Canadian Task Force on Preventive Health Care

18. Association Between Pregnancy Outcomes and Radioactive Iodine Treatment After Thyroidectomy Among Women With Thyroid Cancer (Abstract)

Association Between Pregnancy Outcomes and Radioactive Iodine Treatment After Thyroidectomy Among Women With Thyroid Cancer Current guidelines recommend that women delay pregnancy for 6 to 12 months after the receipt of radioactive iodine treatment (RAIT) following thyroidectomy for differentiated thyroid carcinoma. Although concerns exist regarding the risks associated with pregnancy after RAIT, no large-scale study, to date, has investigated the association between RAIT and pregnancy (...) outcomes.To investigate whether RAIT was associated with increases in adverse pregnancy outcomes among South Korean women who received RAIT after thyroidectomy for thyroid cancer and to evaluate the appropriate interval between RAIT and conception.This population-based cohort study used the Health Insurance Review and Assessment database of South Korea to identify a total of 111 459 women of childbearing age (20-49 years) who underwent thyroidectomy for the treatment of differentiated thyroid carcinoma

2019 EvidenceUpdates

19. Levothyroxine to increase live births in euthyroid women with thyroid antibodies trying to conceive: the TABLET RCT Full Text available with Trip Pro

Levothyroxine to increase live births in euthyroid women with thyroid antibodies trying to conceive: the TABLET RCT Levothyroxine to increase live births in euthyroid women with thyroid antibodies trying to conceive: the TABLET RCT Journals Library An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could not be found. Please choose a page from the navigation or try a website search above to find (...) the information you need. >> >> >> >> Issue {{metadata .Issue }} Toolkit 1)"> 0)"> 1)"> {{metadata.Title}} {{metadata.Headline}} This large trial showed levothyroxine therapy in a dose of 50mcg per day did not improve live birth rates in euthyroid women with thyroid antibodies. {{author}} {{($index , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , & . Rima K Dhillon-Smith 1, 2, 3 , Lee J Middleton 4 , Kirandeep K Sunner 4 , Versha Cheed 4 , Krys Baker 5 , Samantha Farrell-Carver 4 , Ruth Bender

2019 NIHR HTA programme

20. Association Between Levothyroxine Treatment and Thyroid-Related Symptoms Among Adults Aged 80 Years and Older With Subclinical Hypothyroidism. Full Text available with Trip Pro

Association Between Levothyroxine Treatment and Thyroid-Related Symptoms Among Adults Aged 80 Years and Older With Subclinical Hypothyroidism. It is unclear whether levothyroxine treatment provides clinically important benefits in adults aged 80 years and older with subclinical hypothyroidism.To determine the association of levothyroxine treatment for subclinical hypothyroidism with thyroid-related quality of life in adults aged 80 years and older.Prospectively planned combined analysis of data (...) the first trial and 86 from the second trial).Co-primary outcomes were Thyroid-Related Quality of Life Patient-Reported Outcome (ThyPRO) questionnaire scores for the domains of hypothyroid symptoms and tiredness at 1 year (range, 0-100; higher scores indicate worse quality of life; minimal clinically important difference, 9).Of 251 participants (mean age, 85 years; 118 [47%] women), 105 were included from the first clinical trial and 146 were included from the second clinical trial. A total of 212

2019 JAMA